Treatment for HBV-MN Patients in Chinese: An Open Parallel Controlled Trial

N/AUnknownNCT01152060

Nanchang University10 enrolled

Overview

Lamivudine treatment for HBV-DNA negative HBV-GN patients.

lamivudine and predinisone treatment for HBV-DNA negative HBV-GN patients.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Proteinuria HBVe-antigen

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult HBV-GN patients with biopsy-proven MN, heavy protinuria, HBsAg or HBeAg positive, HBV-DNA negative Exclusion Criteria: * Primary MN patients, HBV-DNA positive

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.